Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
94 participants
OBSERVATIONAL
2012-03-31
2017-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Retrospective, Observational, Non-interventional Trial to Assess Eculizumab Treatment Effect in Patients With Atypical Hemolytic Uremic Syndrome (aHUS)
NCT01770951
Evaluation of Potential Predictors of Disease Progression in Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Including Genetics, Biomarkers, and Treatment
NCT02614898
Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-Resistant aHUS
NCT00844545
Atypical Hemolytic-Uremic Syndrome (aHUS) Registry
NCT01522183
To Characterize the Safety and Tolerability of Eculizumab in Two Japanese aHUS Patients
NCT01755429
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* aHUS patients or legal representative who are able and willing to given written informed consent for their study information to be collected and retained in a database.
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Alexion Pharmaceuticals, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Emory Healthcare - Children's Center
Atlanta, Georgia, United States
Dunwoody Pediatrics & Children's Healthcare of Atlanta
Dunwoody, Georgia, United States
Fort Wayne Medical Oncology and Hematology
Fort Wayne, Indiana, United States
Fort Wayne, Indiana, United States
Boston Children's Hospital
Boston, Massachusetts, United States
Henry Ford Health System
Detroit, Michigan, United States
Hudson Valley Oncology Hematology
Hawthorne, New York, United States
Weill Cornell Medical College
New York, New York, United States
Children's Hospital at Montefiore
The Bronx, New York, United States
Cincinnati Children's Hospital
Cincinnati, Ohio, United States
Arthur James Cancer Hospital
Columbus, Ohio, United States
Driscoll Children's Hospital
Corpus Christi, Texas, United States
The Methodist Hospital Research Institute
Houston, Texas, United States
Seattle Children's Hospital
Seattle, Washington, United States
Providence Sacred Heart Medical Center & Children's Hospital
Spokane, Washington, United States
Fox Valley Hematology
Oshkosh, Wisconsin, United States
Royal Adelaide Hospital
North Tce. Adelaide, , Australia
Universitatsklinik fur Innere Medizin Medizinische Universitat Graz
Graz, , Austria
Medizinische Universitaet Innsbruck
Innsbruck, , Austria
UZ Gent Dienst nefrologie
Ghent, , Belgium
Chu Sart Tilman
Liège, , Belgium
Centre Hospitalier Universitaire (CHU) Sainte-Justine
Montreal, , Canada
The Hospital for Sick Children
Toronto, , Canada
Centre Hospitalier Universitaire Pellegrin, Service de Nephrologie Transplantation Dialyse
Bordeaux, , France
CHRU de Caen
Caen, , France
Le Kremlin Bicetre Hospital, Nephrology Unit
Le Kremlin-Bicêtre, , France
CHRU de Lille-Hopital A.Calmette
Lille, , France
Hôpital Edouard Herriot
Lyon, , France
Hopital de la Timone Enfants, Unité de Néphrologie
Marseille, , France
CHU Hotel Dieu
Nantes, , France
Le Centre Hospitalier Universitaire de Nice
Nice, , France
Centre Hospitalier Regional de la Source, Service de nephrologie/hemodialyse
Orléans, , France
Hopital Robert-Debré, Service de Néphrologie Pédiatrique
Paris, , France
Hopital Tenon
Paris, , France
Centre Hospitalier Inter-Communal de Cornouaille
Quimper, , France
CHU-CH Charles Nicolle Pavillon de Pédiatrie
Rouen, , France
Hôpital de Bois Guillaume CHU de Rouen
Rouen, , France
CHU de Saint-Etienne
Saint-Priest-en-Jarez, , France
Nouvel Hopital Civil
Strasbourg, , France
CHRU de Tours
Tours, , France
Universitaetsklinikum Aachen Klinik fuer Nieren- und Hochdruckkrankheiten
Aachen, , Germany
Hannover University Clinic
Hanover, , Germany
Universitaet Heidelberg
Heidelberg, , Germany
A.O. Papa Giovanni XXIII
Bergamo, , Italy
Azienda Ospedaliero-Universitaria Careggi
Florence, , Italy
Istituto Giannina Gaslini
Genova, , Italy
Fondazione IRCCS Ca Granda, Ospedale Maggiore Policlinico Maggiore Policlinico
Milan, , Italy
Ospedale dei Bambini G. di Cristina
Palermo, , Italy
AMC Medical Research B.V.
Amsterdam, , Netherlands
Radboud University Nijmegen Medical Centre Nijmegen
Nijmegen, , Netherlands
Nephrology Clinic, Karolinska University Hospital
Stockholm, , Sweden
INSELSPITAL Universitaetsklinik fuer Kinderheilkunde Kindernephrologie
Bern, , Switzerland
Royal Devon & Exeter NHS Foundation Trust
Exeter, , United Kingdom
Gartnavel General Hospital
Glasgow, , United Kingdom
The Newcastle upon Tyne Hospitals NHS
Newcastle upon Tyne, , United Kingdom
City Hospital, Nottingham University Hospitals, NHS Trust
Nottingham, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Menne J, Delmas Y, Fakhouri F, Licht C, Lommele A, Minetti EE, Provot F, Rondeau E, Sheerin NS, Wang J, Weekers LE, Greenbaum LA. Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study. BMC Nephrol. 2019 Apr 10;20(1):125. doi: 10.1186/s12882-019-1314-1.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
C11-003
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.